595 related articles for article (PubMed ID: 32938761)
1. Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.
Lokugamage KG; Hage A; de Vries M; Valero-Jimenez AM; Schindewolf C; Dittmann M; Rajsbaum R; Menachery VD
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938761
[TBL] [Abstract][Full Text] [Related]
2. Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.
Lokugamage KG; Hage A; de Vries M; Valero-Jimenez AM; Schindewolf C; Dittmann M; Rajsbaum R; Menachery VD
bioRxiv; 2020 Jul; ():. PubMed ID: 32511335
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of SARS-CoV-2 by type I and type III interferons.
Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
5. Antiviral activities of type I interferons to SARS-CoV-2 infection.
Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C
Antiviral Res; 2020 Jul; 179():104811. PubMed ID: 32360182
[TBL] [Abstract][Full Text] [Related]
6. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the IFN-α JAK/STAT Pathway by MERS-CoV and SARS-CoV-1 Proteins in Human Epithelial Cells.
Zhang Y; Gargan S; Roche FM; Frieman M; Stevenson NJ
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458397
[TBL] [Abstract][Full Text] [Related]
8. In vitro inhibition of SARS virus replication by human interferons.
Dahl H; Linde A; Strannegård O
Scand J Infect Dis; 2004; 36(11-12):829-31. PubMed ID: 15764169
[TBL] [Abstract][Full Text] [Related]
9. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
Scagnolari C; Vicenzi E; Bellomi F; Stillitano MG; Pinna D; Poli G; Clementi M; Dianzani F; Antonelli G
Antivir Ther; 2004 Dec; 9(6):1003-11. PubMed ID: 15651759
[TBL] [Abstract][Full Text] [Related]
10. Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.
Schuhenn J; Meister TL; Todt D; Bracht T; Schork K; Billaud JN; Elsner C; Heinen N; Karakoese Z; Haid S; Kumar S; Brunotte L; Eisenacher M; Di Y; Lew J; Falzarano D; Chen J; Yuan Z; Pietschmann T; Wiegmann B; Uebner H; Taube C; Le-Trilling VTK; Trilling M; Krawczyk A; Ludwig S; Sitek B; Steinmann E; Dittmer U; Lavender KJ; Sutter K; Pfaender S
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35131898
[TBL] [Abstract][Full Text] [Related]
11. The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins.
Scagnolari C; Trombetti S; Alberelli A; Cicetti S; Bellarosa D; Longo R; Spanò A; Riva E; Clementi M; Antonelli G
Intervirology; 2007; 50(2):156-60. PubMed ID: 17191018
[TBL] [Abstract][Full Text] [Related]
12. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Sainz B; Mossel EC; Peters CJ; Garry RF
Virology; 2004 Nov; 329(1):11-7. PubMed ID: 15476870
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors.
Kumar A; Ishida R; Strilets T; Cole J; Lopez-Orozco J; Fayad N; Felix-Lopez A; Elaish M; Evseev D; Magor KE; Mahal LK; Nagata LP; Evans DH; Hobman TC
J Virol; 2021 Jun; 95(13):e0026621. PubMed ID: 34110264
[TBL] [Abstract][Full Text] [Related]
14. Evasion of Type I Interferon by SARS-CoV-2.
Xia H; Cao Z; Xie X; Zhang X; Chen JY; Wang H; Menachery VD; Rajsbaum R; Shi PY
Cell Rep; 2020 Oct; 33(1):108234. PubMed ID: 32979938
[TBL] [Abstract][Full Text] [Related]
15. Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.
Subramanian GM; Moore PA; Gowen BB; Olsen AL; Barnard DL; Paragas J; Hogan RJ; Sidwell RW
Chemotherapy; 2008; 54(3):176-80. PubMed ID: 18560223
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection.
Li M; Ayyanathan K; Dittmar M; Miller J; Tapescu I; Lee JS; McGrath ME; Xue Y; Vashee S; Schultz DC; Frieman MB; Cherry S
mBio; 2023 Aug; 14(4):e0119423. PubMed ID: 37377442
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Coronavirus Entry
Outlaw VK; Bovier FT; Mears MC; Cajimat MN; Zhu Y; Lin MJ; Addetia A; Lieberman NAP; Peddu V; Xie X; Shi PY; Greninger AL; Gellman SH; Bente DA; Moscona A; Porotto M
mBio; 2020 Oct; 11(5):. PubMed ID: 33082259
[TBL] [Abstract][Full Text] [Related]
18. Sarbecovirus ORF6 proteins hamper induction of interferon signaling.
Kimura I; Konno Y; Uriu K; Hopfensperger K; Sauter D; Nakagawa S; Sato K
Cell Rep; 2021 Mar; 34(13):108916. PubMed ID: 33765414
[TBL] [Abstract][Full Text] [Related]
19. Interferon-beta 1a and SARS coronavirus replication.
Hensley LE; Fritz LE; Jahrling PB; Karp CL; Huggins JW; Geisbert TW
Emerg Infect Dis; 2004 Feb; 10(2):317-9. PubMed ID: 15030704
[TBL] [Abstract][Full Text] [Related]
20. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-β and IFN inducer.
Shuai H; Chu H; Hou Y; Yang D; Wang Y; Hu B; Huang X; Zhang X; Chai Y; Cai JP; Chan JF; Yuen KY
J Infect; 2020 Oct; 81(4):e1-e10. PubMed ID: 32707230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
